相关实验视频

Updated: Jun 7, 2025

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

由一种用于增强癌症免疫治疗的新型自组合六激素诱导的内在PD-L1降解

Hongxia Zhang¹, Ming Ji¹, Yamei Wang²

¹The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

|November 12, 2024

概括

一种新型的六化物水凝,Gel KFM,通过降低编程死亡配体1 (PD-L1) 的调节和提供化疗,有效地抑制瘤生长. 这种创新方法增强了抗瘤免疫力,并提供了一个有前途的癌症治疗策略.

科学领域:

生物技术是生物技术.
免疫治疗是一种免疫疗法.
材料科学材料科学材料科学

背景情况:

编程死亡配体1 (PD-L1) 是一种关键蛋白质,使瘤能够逃避免疫反应.
目前基于PD-1/PD-L1的抗体抑制剂具有局限性,这导致需要新的治疗方法.

研究的目的:

开发一种新型六 (KFM),可以降低PD-L1的调节,并自组装成ROS响应的超分子水凝.
创建一个双功能的水凝系统,用于局部药物递送和PD-L1抑制.
通过将化疗与PD-L1下调结合起来,提高治疗效果.

主要方法:

合成了一种六 (Lys-Phe-Met-Phe-Met-Lys) 并将其配制成一种对ROS有反应的超分子水凝 (Gel KFM).
装载的凝KFM与米托克桑 (MTX) 和甲胺 (MET) 联合化疗-免疫疗法.
评估了体外和体内疗效,包括瘤生长抑制,CD8+T细胞透和PD-L1表达水平.
研究了PD-L1通过依赖于无素的途径下调的机制.

主要成果:

凝KFM证明了作为局部药物递送系统和PD-L1抑制剂的双重功能.
围口服凝KFM (与MTX和MET) 在体内显著抑制瘤生长.
观察到增强的CD8+T细胞透和减少内PD-L1表达.
发现KFM通过一种依赖于无素的机制促进PD-L1降解.

结论:

这种无载体输送系统将超分子基转化为活性免疫治疗剂.
凝KFM通过将化疗与向PD-L1降低调节相结合,代表了癌症治疗的有前途的新策略.
这项研究强调了自我组装在开发先进的癌症治疗中的潜力.

关键词:

在PD-L1下调器下.无载体瘤疗法无载体瘤疗法自组装的自组合.这是一种超分子凝.

更多相关视频

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

相关概念视频

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.